This article is more than 5 years old. Information may no longer be current.
AMD treatment may be effective in ocular histoplasmosis syndrome
Click Here to Manage Email Alerts
Photodynamic therapy with verteporfin may be effective in treating ocular histoplasmosis syndrome, a study published in the August issue of Ophthalmology concludes.
As part of the Verteporfin in Ocular Histoplasmosis Study, 25 patients with ocular histoplasmosis syndrome (OHS) who also had subfoveal neovascularization received verteporfin infused over 10 minutes. Fifteen minutes after the start of the infusion, the laser portion of the treatment was initiated. At the 3-month follow-up, re-treatment was applied if the angiography showed fluorescein leakage.
By the 1-year mark, patients had received an average of 2.9 treatments of a maximum four. The median improvement from baseline in visual acuity was seven letters, and median contrast sensitivity improved by 2 letters. At the 1-year point, 14 patients (56%) gained visual acuity and four patients (16%) lost some acuity. No serious systemic or adverse events were reported.